Depo Provera And Meningioma

                                        

                                                                         Progestrone 

	Made naturally by the ovaries, placenta, and adrenal glands
	Identical to hormone in human body
	Short (~5 minutes in blood)
	Acts on progesterone receptors
	Regulates menstrual cycle, supports pregnancy

                                                      Progestrone To Depo Provera

                                            Depo Provera (Chemical Modification Of Progestrone)

Fully synthetic, made from chemical modification of progesterone
Modified molecule (acetate group added) for longer activity
Long (active for ~12–14 weeks after injection)
Acts on progesterone receptors and has some glucocorticoid activity
Prevents ovulation, thins uterine lining, thickens cervical mucus

         Depo Provera And Meningioma 

Observational Studies

• High-dose, long-term MPA for medical conditions (e.g., cancer, endometriosis) has been associated with higher meningioma incidence.

• Recent case–control studies:

  • France (2023) – Long-term use of high-dose oral or injectable MPA was linked to an increased risk of intracranial meningioma, especially at doses ≥200–300 mg/month for multiple years.

  • UK & International Data – Suggest that risk is more pronounced with continuous high-dose therapy, not short-term contraceptive dosing.

• For contraceptive 150 mg IM every 3 months, most large studies have not shown a strong risk, though some data suggest a small increase with >5 years continuous use.

Snapshot